AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
AIM ImmunoTech announced that its CEO, Thomas K. Equels, will participate in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech announced that its CEO, Thomas K. Equels, will participate in two upcoming investor conferences. The first event, the Healthcare Company Showcase hosted by Alliance Global Partners, will take place on May 21, 2024, at 3:20 PM ET. The second event, LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar, is scheduled for May 22, 2024, at 3:40 PM ET. Both presentations will be webcast live and accessible via the Events page on AIM ImmunoTech's Investor section of their website.
Positive
- CEO participation in two investor conferences can increase visibility for AIM.
- Live webcasts allow broader access to the company's presentations.
Negative
- No new financial or clinical data was provided in the announcement.
- Participation in conferences alone may not significantly impact stock performance without substantial updates.
Details
News Market Reaction – AIM
The recorded move for AIM in the trading session of this news was +2.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.
Details for the presentations are as follows:
Event: Healthcare Company Showcase hosted by Alliance Global Partners
Date and Time: Tuesday, May 21, 2024, at 3:20 PM ET
Webcast Link
Event: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date and Time: Wednesday, May 22, 2024, at 3:40 PM ET
Webcast Link
Live webcasts of the presentations will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.